NCT02886598已完成不适用
Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Firmagon® (Degarelix) for Injection
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 368
- 试验地点
- 1
- 主要终点
- Incidence of adverse events
研究概览
简要总结
The purpose of this study is to assess the safety and efficacy of Firmagon® (degarelix) for injection under the conditions of general clinical practice in Korea.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients who are eligible for the treatment of Firmagon® (degarelix) for injection according to the approved product label, and Firmagon® (degarelix) treatment decided before study enrolment. Moreover, patient should have not previously received Firmagon® (degarelix) for injection before the study commencement date at each site. - Indication: treatment of advanced, hormone-dependent prostate cancer.
排除标准
- •Patients with previous or concurrent known hypersensitivity to any component of the drug.
研究组 & 干预措施
Firmagon®
Treatment according to standard clinical practice.
干预措施: degarelix (Drug)
结局指标
主要结局
Incidence of adverse events
时间窗: Up to 12 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
撤回
不适用
A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisRheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritisNCT01692457Janssen Pharmaceutica
Unknown
4 期
the Safety and Efficacy of Collagen Injection in Patients With Plantar FasciitisPlantar FasciitisNCT02539082Sewon Cellontech Co., Ltd.60
终止
不适用
Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in PhilippinesInfections, StreptococcalNCT01046097GlaxoSmithKline28
已完成
不适用
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and AboveInfluenzaNCT05406180Sanofi675
终止
不适用
Safety and Efficacy of Fibryga in Congenital Fibrinogen DeficiencyCongenital Fibrinogen DeficiencyNCT03793426Octapharma7